Christopher Hall Sells 100,000 Shares of Personalis (NASDAQ:PSNL) Stock

Personalis, Inc. (NASDAQ:PSNL) CEO Christopher Hall sold 100,000 shares of the firm’s stock in a transaction that occurred on Friday, June 26th. The stock was sold at an average price of $13.15, for a total transaction of $1,315,000.00. Following the transaction, the chief executive officer directly owned 235,986 shares in the company, valued at $3,103,215.90. This represents a 29.76% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Personalis Trading Up 3.4%

NASDAQ PSNL opened at $13.02 on Friday. The company has a market cap of $1.36 billion, a price-to-earnings ratio of -12.76 and a beta of 2.28. The company has a 50 day moving average of $8.42 and a 200-day moving average of $8.29. Personalis, Inc. has a 1-year low of $3.84 and a 1-year high of $13.37.

Personalis (NASDAQ:PSNL) last issued its quarterly earnings results on Thursday, May 7th. The company reported ($0.29) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.23) by ($0.06). Personalis had a negative return on equity of 43.52% and a negative net margin of 148.11%.The company had revenue of $15.47 million for the quarter, compared to analyst estimates of $14.48 million. On average, equities research analysts forecast that Personalis, Inc. will post -1.06 earnings per share for the current year.

Hedge Funds Weigh In On Personalis

Several hedge funds and other institutional investors have recently modified their holdings of the business. Royal Bank of Canada raised its holdings in shares of Personalis by 3.2% during the 1st quarter. Royal Bank of Canada now owns 78,341 shares of the company’s stock worth $275,000 after buying an additional 2,395 shares in the last quarter. Dynamic Technology Lab Private Ltd lifted its position in shares of Personalis by 75.6% during the 1st quarter. Dynamic Technology Lab Private Ltd now owns 76,729 shares of the company’s stock worth $269,000 after buying an additional 33,044 shares during the last quarter. Goldman Sachs Group Inc. boosted its stake in Personalis by 55.7% in the first quarter. Goldman Sachs Group Inc. now owns 284,426 shares of the company’s stock valued at $998,000 after buying an additional 101,706 shares in the last quarter. Focus Partners Wealth acquired a new stake in Personalis in the first quarter valued at about $47,000. Finally, JPMorgan Chase & Co. grew its position in Personalis by 505.6% in the second quarter. JPMorgan Chase & Co. now owns 29,491 shares of the company’s stock valued at $193,000 after acquiring an additional 24,621 shares during the last quarter. Institutional investors own 61.91% of the company’s stock.

Wall Street Analysts Forecast Growth

PSNL has been the topic of a number of recent analyst reports. BTIG Research decreased their price target on Personalis from $13.00 to $11.00 and set a “buy” rating on the stock in a research report on Monday, May 11th. Wall Street Zen cut shares of Personalis from a “hold” rating to a “sell” rating in a research report on Saturday, June 13th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Personalis in a research note on Tuesday, April 21st. Finally, Morgan Stanley decreased their target price on shares of Personalis from $10.00 to $9.00 and set an “equal weight” rating on the stock in a report on Tuesday, May 12th. Five analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Personalis has an average rating of “Moderate Buy” and a consensus price target of $11.00.

About Personalis

Personalis, Inc (NASDAQ: PSNL) is a clinical‐stage genomics company that develops and markets advanced next‐generation sequencing (NGS) services and assays designed to accelerate precision medicine. The Company’s core offering is the ImmunoID NeXT™ Platform, which combines comprehensive tumor profiling—including whole exome, transcriptome, and T‐cell receptor sequencing—with proprietary bioinformatics to identify biomarkers and guide immuno‐oncology research. Personalis serves biopharmaceutical companies, academic institutions, and clinical research organizations seeking in‐depth insights into cancer, autoimmune diseases and other complex conditions.

In addition to its flagship ImmunoID NeXT™ Platform, Personalis offers a suite of customizable sequencing assays for biomarker discovery, clinical trial support and companion diagnostic development.